Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.17 HKD
Change Today +0.24 / 3.46%
Volume 1.3M
As of 4:01 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

dawnrays pharmaceutical hold (2348) Snapshot

Open
$6.93
Previous Close
$6.93
Day High
$7.19
Day Low
$6.92
52 Week High
10/22/14 - $8.13
52 Week Low
02/11/15 - $3.91
Market Cap
5.8B
Average Volume 10 Days
1.4M
EPS TTM
$0.25
Shares Outstanding
804.3M
EX-Date
05/27/15
P/E TM
22.5x
Dividend
$0.11
Dividend Yield
1.30%
Current Stock Chart for DAWNRAYS PHARMACEUTICAL HOLD (2348)

Related News

No related news articles were found.

dawnrays pharmaceutical hold (2348) Related Businessweek News

No Related Businessweek News Found

dawnrays pharmaceutical hold (2348) Details

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. The company operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. It offers cephalosporin antibiotics cover intermediates, bulk medicines, and powder for injections; and specific medicines covering therapeutic areas for anti-HBV, anti-allergic, cardiovascular system, digestive system, urinary system, and endocrine system with dosage forms of tablets, capsules, and granules. The company was founded in 1995 and is headquartered in Wanchai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.

950 Employees
Last Reported Date: 04/10/15
Founded in 1995

dawnrays pharmaceutical hold (2348) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: CNY867.0K
Co-Founder and Executive Director
Total Annual Compensation: CNY534.0K
Executive Director
Total Annual Compensation: CNY534.0K
Compensation as of Fiscal Year 2014.

dawnrays pharmaceutical hold (2348) Key Developments

Dawnrays Pharmaceutical Holdings Ltd. Presents at Credit Suisse Asia Healthcare C-Level Conference, May-21-2015

Dawnrays Pharmaceutical Holdings Ltd. Presents at Credit Suisse Asia Healthcare C-Level Conference, May-21-2015 . Venue: Credit Suisse Office, Level 88, International Commerce Center, 1 Austin Road West, Kowloon, Hong Kong.

Dawnrays Pharmaceutical Holdings Ltd., Annual General Meeting, May 22, 2015

Dawnrays Pharmaceutical Holdings Ltd., Annual General Meeting, May 22, 2015., at 10:00 China Standard Time. Location: Plaza 3, Novotel Century Hong Kong Hotel,. Agenda: To receive and consider the audited consolidated financial statements and the reports of the directors and the auditors for the financial year ended 31 December 2014; to declare a final dividend; to re-appoint auditors and to authorize the board to fix their remuneration; to consider re-elect of directors; and to consider other matter also.

Dawnrays Pharmaceutical Holdings Ltd. Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2014; Recommends Final Dividend Payable on June 9, 2015

Dawnrays Pharmaceutical Holdings Ltd. announced audited consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenue of RMB 783,803,000 against RMB 914,973,000 a year ago. Profit before tax was RMB 258,893,000 against RMB 188,966,000 a year ago. Profit attributable to owners of the parent was RMB 205,145,000 against RMB 153,099,000 a year ago. Diluted earnings per share attributable to ordinary equity holders of the parent were RMB 0.2540 against RMB 0.1908 a year ago. The decrease in turnover was mainly attributable to the reduction in production from the cephalosporin product line, while the increase in profit was mainly attributable to the satisfactory sustained sales performance of the Group's system specific medicines. The company proposed final dividend per share of HKD 0.085 against HKD 0.068 last year. The payment of the final dividend amounting to the total sum of approximately HKD 68,235,000 to the shareholders whose names appeared in the register of members as of June 1, 2015 is subject to the approval of the shareholders at the forthcoming 2015 annual general meeting to be held on May 22, 2015. Taking into consideration the interim dividend of HKD 0.025 per share, the total annual dividend distributed for the year is HKD 0.11 per share. The dividend payout ratio is approximately 34.5%. The dividend is payable on June 9, 2015 to shareholders.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2348:HK $7.17 HKD +0.24

2348 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2348.
View Industry Companies
 

Industry Analysis

2348

Industry Average

Valuation 2348 Industry Range
Price/Earnings 21.8x
Price/Sales 5.7x
Price/Book 3.6x
Price/Cash Flow 21.8x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAWNRAYS PHARMACEUTICAL HOLD, please visit www.dawnrays.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.